Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Mavoglurant - STALICLA

Next Previous
Drug Profile

Mavoglurant - STALICLA

Alternative Names: AFQ-056; STP-7

Latest Information Update: 02 Dec 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis
  • Developer National Institute of Drug Abuse; Novartis; STALICLA
  • Class Alkynes; Antiparkinsonians; Anxiolytics; Drug withdrawal therapies; Esters; Indoles; Neuropsychotherapeutics; Nitriles; Small molecules
  • Mechanism of Action Metabotropic glutamate receptor 5 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Alcoholism
  • Phase I Cocaine-related disorders
  • Discontinued Anxiety disorders; Chorea; Drug-induced dyskinesia; Fragile X syndrome; Gastro-oesophageal reflux; Obsessive-compulsive disorders; Smoking withdrawal

Most Recent Events

  • 07 Oct 2024 Stalicla completes a phase I trial in Cocaine-related disorders (In volunteers, Treatment-naive) in USA (PO) (NCT06273540)
  • 01 Jul 2024 Phase-II clinical trials in Alcoholism in USA (PO) (NCT06136195)
  • 15 Apr 2024 Phase-I clinical trials in Cocaine-related disorders (In volunteers, Treatment-naive) in USA (PO) (NCT06273540)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top